Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions
The Pharma Data
JANUARY 13, 2021
We are developing the manufacturing processes for TNX-1500 and expect Good Manufacturing Practice (GMP) TNX-1500 to be available in the third quarter of 2021. CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. antagonist receptor fusion protein. Structure.
Let's personalize your content